Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_assertion type Assertion NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_head.
- NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_assertion description "[Adjunctive therapy with recombinant human IGF-I (rhIGF-I)/recombinant human IGF binding protein-3 (rhIGFBP-3) has been shown to improve insulin sensitivity in both type 1 and type 2 diabetes and may have a role in the treatment of SIR.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_provenance.
- NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_assertion evidence source_evidence_literature NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_provenance.
- NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_assertion SIO_000772 20233784 NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_provenance.
- NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_assertion wasDerivedFrom befree-2016 NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_provenance.
- NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_assertion wasGeneratedBy ECO_0000203 NP800309.RAVd0QCOCi0U71S16XdFyEFV3287veK8ZBfu7IPghnSjQ130_provenance.